The diagnosis of COPD is recommendation dependent

##plugins.themes.academic_pro.article.sidebar##

Published Jan 28, 2015
Download
pdf
Vol. 92 No. 7 (2014): Issue Jul 2014

##plugins.themes.academic_pro.article.main##

Helmi Ben Saad
Leila Ben Amor
Samia Ben Mdella
Ines Ghannouchi
Mejda Ben Essghair
Iheb Bougmiza
Abdelhamid Garrouche
Naceur Rouatbi
Sonia Rouatbi

Abstract

Background: Different spirometric criteria are recommended to diagnosis chronic obstructive pulmonary disease (COPD): -American Thoracic Society/European Respiratory Society (ATS/ERS), Global initiative for chronic Obstructive Lung Disease (GOLD): a post bronchodilator (PBD) ratio between the 1st second Forced Expiratory Volume and Forced Vital Capacity (FEV1/FVC) < 0.70; -Thoracic Society of Australia and New Zealand (ANZTS): a PBD FEV1/FVC < 0.70 and a PBD FEV1 < 80%; -British Thoracic Society (BTS): a before BD (BBD) FEV1/FVC < 0.70 and a BBD FEV1 < 80%; -Old criterion retained, till 2010, by the French Society of Pneumology (SPLF): a PBD ratio between FEV1 and slow vital capacity < 0.70.

Aim: To determine, according to the different recommendations, the percentage of smokers having COPD among a population of smokers of more than 40 Packets/Year (PY) addressed for plethysmography. Methods: The plethysmographic data of 531 consecutive stable male smokers that underwent reversibility testing (400 µg of Salbutamol®) were analyzed.

Results: The mean±SD of age, cigarettes consumption, PBD FEV1 (%), were, respectively, 61±11 Yr, 64±20 PY and 52±21%. The percentages of subjects having COPD according to the above criteria were 75.5% (SPLF old criterion); 71.2% (ATS/ERS, GOLD); 70.8% (BTS) and 69.7% (ANZTS).

Conclusion: The diagnosis of COPD depends on which guidelines are used for defining the disease. This forms a barrier to early diagnosis, affects public health decisions and wrong planning strategies.

Keywords:

Key-words. Spirometry - FEV1/SVC - FEV1/FVC - Diagnosis - COPD - Guidelines

##plugins.themes.academic_pro.article.details##

References

  1. Celli BR, MacNee W, ATS/ERS task force. Standards for the diagnosis and treatment of patients with COPD : a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-46.
  2. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, GOLD executive summary. Am J Respir Crit Care Med 2013;187:347-65
  3. Australian lung foundation; thoracic society of Australia and New Zealand. The COPDX Plan: Australian and New Zealand guidelines for the management of chronic obstructive pulmonary disease 2008. www.copdx.org.au (visité le 2.6.2013)
  4. British thoracic Society. Diagnosing COPD. Thorax 2004;59: 27-38
  5. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R et al. Série du groupe de travail ATS/ERS: «standardisation des explorations fonctionnelles respiratoires»: stratégies d'interprétation des explorations fonctionnelles respiratoires. Rev Mal Respir 2006; 23: 17S79-17S104.
  6. Bougrida M, Ben Saad H, Kheireddinne Bourahli M, Bougmiza I, Mehdioui H. Équations de référence spirométriques des Algériens âgés de 19 à 73 ans. Rev Mal Respir 2008;25:577-90.
  7. Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J, Howard P et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European respiratory society task force. Eur Respir J 1995;8:1398-420.
  8. Société de pneumologie de langue française. Updated guidelines of the Société de Pneumologie de Langue Française for the management of chronic obstructive pulmonary disease: essential points. Rev Mal Respir 2003;20(2 Pt 1):294-9.
  9. Ben Saad H, Ben Attia Saafi R, Rouatbi S, Ben Mdella S, Garrouche A, Zbidi A et al. Quelle définition faut-il choisir pour le déficit ventilatoire obstructif ? Rev Mal Respir 2007;24:323-30.
  10. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH et al. ERS Global Lung Function Initiative. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J 2012;40:1324-43.
  11. Johannessen A, Lehmann S, Omenaas ER, Eide GE, Bakke PS, Gulsvik A. Post-bronchodilator spirometry values in adults and implications for disease management. Am J Respir Crit Care Med 2006;173:1316-25
  12. Pérez-Padilla R, Torre Bouscoulet L, Vázquez-García JC, Muiño A, Márquez M, López MV et al. Grupo PLATINO. Spirometry reference values after inhalation of 200 microg of salbutamol. Arch Bronconeumol 2007;43:530-4.
  13. Beasley R, Weatherall M, Travers J, Shirtcliffe P. Time to define the disorders of the syndrome of COPD. Lancet 2009;374:670-2.
  14. Le groupe Pulmonaria, Quanjer PH, Enright PL, Stocks J, Ruppel G, Swanney MP, Crapo RO et al. Open letter to the members of the GOLD committee. Rev Mal Respir 2010;27:1003-7. http://www.splf.org/s/ IMG/pdf/Letter_ to_members_of_GOLD_ committee. pdf (visité le 2.11.2013)
  15. Tabka Z, Hassayoune H, Guenard H, Zebidi A, Commenges D, Essabah H et al. Spirometric reference values in a Tunisian population. Tunis Med 1995;73:125-31.
  16. Ben Saad H, Rouatbi S, Raoudha S, Tabka Z, Laouani Kechrid C, Hassen G et al. Vital capacity and peak expiratory flow rates in a NorthAfrican population aged 60 years and over: influence of anthropometric data and parity. Rev Mal Respir 2003;20:521-30
  17. Ben Saad H, Tfifha M, Harrabi I, Tabka Z, Guenard H, Hayot M et al. Factors influencing pulmonary function in Tunisian women aged 45 years and more. Rev Mal Respir 2006;23:324-38.
  18. Anthonisen NR, Wright EC. Bronchodilator response in chronic obstructive pulmonary disease. Am Rev Respir Dis 1986;133:814-9.
  19. Roche N, Dalmay F, Perez T, Kuntz C, Vergnenègre A, Neukirch F et al. FEV1/FVC and FEV1 for the assessment of chronic airflow obstruction in prevalence studies : do prediction equations need revision ? Respir Med 2008;102:1568-74.
  20. Jenicek M, Cleroux R. Epidémiologie: principes techniques. Applications.Edisem inc., Maloine Paris, 1982, 430.
  21. . Benali R, Ben Saad H, Harrabi I, Atek M, Zidouni N, Prefaut C. Management of COPD: feasability. Rev Mal Respir 2006;23:1049-50.
  22. Ferris BG. Epidemiology standardization project II : Recommended respiratory disease questionnaires for use with adults and children in epidemiological research. American Thoracic Society. Am Rev Respir Dis 1978,118:1-120.
  23. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A et al. Série du groupe de travail ATS/ERS: «standardisation des explorations fonctionnelles respiratoires»: Standardisation de la spirométrie. Rev Mal Respir 2006; 23: 17S23-17S45.
  24. Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F et al. Série du groupe de travail ATS/ERS: «standardisation des explorations fonctionnelles respiratoires» : Standardisation de la mesure des volumes pulmonaires. Rev Mal Respir 2006; 23: 17S47-17S60.
  25. Raherison C, Biron E, Nocent-Ejnaini C, Taillé C, Tillie-Leblond I, Prudhomme A. Are there specific characteristics of COPD in women? Rev Mal Respir 2010;27:611-24.
  26. Barnes PJ. Mechanisms in COPD: differences from asthma. Chest 2000;117:10-40.
  27. Griffith KA, Sherrill DL, Siegel EM, Manolio TA, Bonekat HW, Enright PL. Predictors of loss of lung function in the elderly: the cardiovascular health study. Am J Respir Crit Care Med 2001;163:61-8.
  28. Ben Saad H, Préfaut C, Tabka Z, Zbidi A, Hayot M. The forgotten message from GOLD: FVC is a primary clinical outcome measure of bronchodilator reversibility in COPD. Pulm Pharmacol Ther 2008;21:767-73.
  29. . Ben Saad H, Ben Amor L, Ben Mdalla S, Ghannouchi I, Ben Essghair M, Sfaxi R et al. Place de la distension pulmonaire dans l'exploration des gros fumeurs de cigarettes. Rev Mal Respir 2013 (in press). DOI: 10.1016/j.rmr.2013.05.009.
  30. Lindberg A, Jonsson AC, Rönmark E, Lundgren R, Larsson LG, Lundbäck B. Prevalence of chronic obstructive pulmonary disease according to BTS, ERS, GOLD and ATS criteria in relation to doctor's diagnosis, symptoms, age, gender, and smoking habits. Respiration 2005;72:471-9.
  31. Nathell L, Nathell M, Malmberg P, Larsson K. COPD diagnosis related to different guidelines and spirometry techniques. Respir Res 2007;8:89.
  32. British thoracic society. BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD guidelines group of the standards of care committee of the BTS. Thorax 1997;52 (Suppl 5):1-28.
  33. ATS. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;152:77- 121.
  34. Celli BR, Halbert RJ, Isonaka S, Schau B. Population impact of different definitions of airway obstruction. Eur Respir J 2003; 22:268-73.
  35. Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J, Howard P et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European respiratory society task force. Eur Respir J 1995;8:1398-420.
  36. Viegi G, Pedreschi M, Pistelli F, Di Pede F, Baldacci S, Carrozzi L et al. Prevalence of airway obstruction in general population : European respiratory society - American thoracic society definition. Chest 2000;117:339S-45S.
  37. European respiratory society. Standardized lung function testing. Eur Respir J 1993;19:1-95.
  38. ATS/American Thoracic Society. Lung function testing: Selection of reference values and interpretative strategies. Am Rev Respir Dis 1991;144:1202-18
  39. Roberts SD, Farber MO, Knox KS, Phillips GS, Bhatt NY, Mastronarde JG et al. FEV1/FVC ratio of 70% misclassifies patients with obstruction at the extremes of age. Chest 2006;130:200-6
  40. Roche N. Early detection of COPD: interest, objective, means. Souffle 2004;7:33-8.
  41. Halpin D. NICE guidance for COPD. Thorax 2004;59:181-2.
  42. Keaney N, Kay A, Taylor I. Guidelines and the diagnosis of COPD. Am J Respir Crit Care Med 2009;179:734.
  43. Johannessen A, Omenaas ER, Bakke PS, Gulsvik A. Implications of reversibility testing on prevalence and risk factors for chronic obstructive pulmonary disease: a community study. Thorax 2005;60:842-7.